Assessing risk and improving survival in lymphoma

摘要

Lymphoma represents the sixth most common form of cancer in the UK, with non-Hodgkin lymphoma (NHL) representing 4% and Hodgkin lymphoma (HL) <1% of cases; over 13 000 lymphoma cases are diagnosed annually1,2 and its incidence, in particular NHL, has continued to rise over recent decades.3 There are now more than 40 recognised lymphoma subtypes and this contributes to its heterogeneity of clinical presentation, ranging from subtle signs and symptoms to acutely unwell cases with end-organ compromise.